Tirzepatide is a 39–amino-acid synthetic peptide engineered to bind two incretin receptors — GIP and GLP-1. Supplied as a lyophilized powder in sterile vials with 3rd-party HPLC verification and full Certificate of Analysis per lot.
Tirzepatide is described in published literature as the first dual GIP/GLP-1 receptor agonist. Originally developed by Eli Lilly (trade names Mounjaro and Zepbound), it is characterized in the literature by its ability to bind and activate two distinct incretin receptors from a single molecule.
The compound is a 39-residue synthetic peptide with a C20 fatty diacid conjugate at position 20 (K20), a modification that increases its affinity for serum albumin and extends its reported half-life to approximately five days.
Published pharmacology studies describe tirzepatide as acting at both the GIP receptor and the GLP-1 receptor. At the GLP-1 receptor, the literature reports downstream effects on gastric emptying and glucose-dependent insulin secretion. At the GIP receptor, reported effects include modulation of metabolic signaling pathways.
The molecule is supplied as a lyophilized powder — white to off-white in appearance — with a molecular weight of 4,813 Da. Reported solubility is in bacteriostatic water or sodium chloride 0.9%. Stability data in the literature indicates the lyophilized form is stable at 2–8°C for up to 24 months and the reconstituted form for approximately 28 days under refrigeration.
The compound's lipidation pattern (γGlu-C20 diacid at K20) is functionally analogous to the lipid modifications used in other once-weekly GLP-1 analogs, reflecting a broader design trend toward albumin-binding modifications for extended pharmacokinetic profiles.
The above summarizes published research literature and regulatory filings. This is not medical advice, a protocol, or a recommendation for use. This compound is supplied for laboratory research only.
Every lot is tested by an independent 3rd-party analytical laboratory before release. The standard analytical panel includes reverse-phase HPLC (minimum 99.5% release spec, typically >99.9%), mass spectrometry for identity confirmation, Karl Fischer for water content, LAL assay for endotoxin (<0.25 EU/mL), bioburden, and sterility testing per USP <71>.
The resulting Certificate of Analysis PDF is attached to every order and is lookup-able by lot number after the fact.
Structurally, they're both synthetic peptides designed as long-acting incretin analogs. Semaglutide binds only the GLP-1 receptor (mono-agonist). Tirzepatide binds both GLP-1 and GIP receptors (dual-agonist) — a design choice intended to broaden the metabolic signaling profile from a single molecule.
In pharmacology comparisons reported in the literature, tirzepatide shows distinct receptor binding kinetics at each target. The SURPASS-2 trial published in NEJM (2021) reported head-to-head comparative data.
Shipped at ambient temperature in discreet, tamper-evident packaging. Lyophilized peptide powder is stable at room temperature for typical transit windows, which is why research-grade vendors ship this way without cold-chain logistics. Tracked via carrier; signature not required.
Upon receipt, store the unopened lyophilized vial refrigerated at 2–8°C and protected from light. Literature reports the lyophilized form is stable for up to 24 months under these conditions. If reconstituted per published solubility data, the solution is typically stable for approximately 28 days at 2–8°C. Do not freeze.
Tirzepatide is a 39-amino-acid synthetic peptide with a molecular formula of C225H348N48O68 and a monoisotopic mass of 4,813.45 Da. It carries a γGlu-C20 fatty diacid conjugate at position 20 (K20) — a lipidation pattern designed to increase albumin binding and extend the compound's reported half-life.
Supplied as a white to off-white lyophilized powder. The full primary structure and reference data are in the Compound Profile section above.
All compounds are synthesized by qualified partner laboratories operating under standard peptide synthesis practices. Synthesis records, raw material provenance, and release testing are documented in the lot file.
Each lot is independently verified by a 3rd-party analytical lab — not our in-house testing — before release. The COA PDF identifies the release lab, the method, and the analyst.
Domestic US shipping to all 50 states via USPS / UPS. Tracking provided at dispatch. International shipping is evaluated on a case-by-case basis due to jurisdictional import regulations.
All products offered on this site are intended for laboratory research purposes only. They are not for human consumption, oral ingestion, or any form of in-vivo use in humans or animals. These compounds are not medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease.
By placing an order you acknowledge that you are a qualified researcher over the age of 21 and that you assume all responsibility for handling, storage, and end use of the compounds in accordance with applicable law.
HPLC-verified. Mass-spec confirmed. Ambient-stable transit. The paperwork other vendors hope you never ask for.
⚠ ALL PRODUCTS ARE INTENDED FOR LABORATORY RESEARCH PURPOSES ONLY. NOT FOR HUMAN CONSUMPTION, ORAL INGESTION, OR ANY FORM OF IN-VIVO USE IN HUMANS OR ANIMALS. THESE COMPOUNDS ARE NOT MEDICINES OR DRUGS AND HAVE NOT BEEN APPROVED BY THE FDA. BY PLACING AN ORDER YOU ACKNOWLEDGE YOU ARE A QUALIFIED RESEARCHER OVER THE AGE OF 21.